Sugi Predict

Sugi Predict / Targets / SUPT16H

SUPT16H

FACT complex subunit SPT16 · Q9Y5B9 · SUPT16H on Sugi Atlas →

0 patent compounds predicted against SUPT16H, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SUPT16H by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma PHASE1WITHDRAWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
SMN Circular RNAs as Potential Biomarkers for the Therapeutic Response to Nusinersen in Spinal Muscular Atrophy Patients nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis nanCOMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Mechanisms of Cell Death in Spinal Muscular Atrophy nanCOMPLETED
Genome Medical Sequencing for Gene Discovery nanRECRUITING
Shwachman Diamond Syndrome Registry and Study nanRECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy nanCOMPLETED
Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SUPT16H binder may also engage these)

ProteinNameSimilarity
Q920B9 — 1.000 Q920B9 →
Q8IRG6 — 1.000 Q8IRG6 →
Q8X0X6 — 0.999 Q8X0X6 →
Q9W603 — 0.998 Q9W603 →
Q5B2X8 — 0.997 Q5B2X8 →
Q4WJ02 — 0.992 Q4WJ02 →
Q61E63 — 0.992 Q61E63 →
Q4P2U5 — 0.991 Q4P2U5 →
Q6FWT4 — 0.990 Q6FWT4 →
Q2UBF1 — 0.990 Q2UBF1 →
Q4HYB8 — 0.989 Q4HYB8 →
Q39601 — 0.989 Q39601 →
Q6C7V4 — 0.988 Q6C7V4 →
Q5A1D5 — 0.988 Q5A1D5 →
P32558 — 0.988 P32558 →
Q4H2R2 — 0.988 Q4H2R2 →
O94267 — 0.987 O94267 →
Q6BXE5 — 0.987 Q6BXE5 →
Q05153 — 0.987 Q05153 →
Q6C931 — 0.986 Q6C931 →
Q23670 — 0.986 Q23670 →
B4KN00 — 0.986 B4KN00 →
Q9N5R9 — 0.986 Q9N5R9 →
P0CQ22 — 0.986 P0CQ22 →
P0CQ23 — 0.986 P0CQ23 →
Q9WVK4 — 0.986 Q9WVK4 →
Q5E9R3 — 0.985 Q5E9R3 →
Q9M2Q4 — 0.985 Q9M2Q4 →
Q6PFQ2 — 0.984 Q6PFQ2 →
B4MRZ8 — 0.984 B4MRZ8 →